Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | ACP3 | P15309 | 11/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | PGK2 | P07205 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565838 | 0.79 | SRC (0.54) | SRCACP3PGK1PGK2 | |
| SCHEMBL777991 | 0.73 | ACP3 (0.53) | SRCACP3PTPN1PGK1PGK2 | |
| SCHEMBL5158165 | 0.73 | SRC (0.47) | SRCACP3PTPN1 | |
| SCHEMBL5256535 | 0.71 | PGK1 (0.77) | SRCACP3PGK1PGK2 | |
| SCHEMBL779181 | 0.71 | PTPN5 (0.40) | ACP3PTPN1PGK1PGK2 | |
| SCHEMBL776864 | 0.71 | ACP3 (0.58) | SRCACP3PTPN1 | |
| SCHEMBL232244 | 0.70 | ACP3 (0.79) | SRCACP3PGK1PGK2 | |
| SCHEMBL4094661 | 0.70 | SRC (1.00) | SRCACP3PGK1PGK2 | |
| SCHEMBL382252 | 0.70 | ACP3 (0.42) | SRCACP3PTPN1 | |
| SCHEMBL1276957 | 0.69 | POLB (0.51) | SRCACP3PTPN1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071110-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2842559-A2 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | Chimerix, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051174-A1 | Phosphonate Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| US-8846978-B2 | Electronic devices comprising novel phosphonic acid surface modifiers | IMPERIAL INNOVATIONS LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| EP-1233770-A4 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1233770-A2 | PHOSPHONATE COMPOUNDS | The Regents of The University of California at San Diego (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6416737-B1 | SCREENING COMPOUNDS (BISPHOSPHONATES SUCH AS ALENDRONATES) THAT INCREASE BONE STRENGTH BY CONTACTING OSTEOCYTES WITH THE COMPOUND, MEASURING THE APOPTOSIS OF THE CELLS, AND SELECTING THE COMPOUND THAT INHIBITS APOPTOSIS IN OSTEOBLASTS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2002-07-09 | — | — | US | disclosed |
| EP-1121132-A1 | METHOD AND COMPOSITIONS FOR INCREASING BONE MASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001039724-A2 | PHOSPHONATE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000028982-A2 | INCREASING BONE STRENGTH WITH SELECTED BISPHOSPHONATES | THE BOARD OF TRUSTEES FOR THE UNIVERSITY OF ARKANSAS (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000020007-A1 | METHOD AND COMPOSITIONS FOR INCREASING BONE MASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5532226-A | FOR INCREASING BONE FORMATION AND BONE MASS IN MAMMALS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| US-5300687-A | Trifluoromethylbenzylphosphonates useful in treating osteoporosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0524023-A1 | Trifluoromethylbenzylphosphonates useful in treating osteoporosis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051174-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | SRC 1342/4885ACP3 17/4885PTPN1 1142/4885 |
| US-10071110-B2 | Phosphonate compounds | PHPT1, PHOSPHO1, PIK3CA | SRC 1342/4885ACP3 17/4885PTPN1 1142/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | SRC 1342/4885ACP3 17/4885PTPN1 1142/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | SRC 1342/4885ACP3 17/4885PTPN1 1142/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | SRC 3219/4885ACP3 971/4885PTPN1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.